30-Aug-2018 | Zion Market Research
Zion Market Research has published a new report titled “Stem Cell Therapy Market by Type (Allogenic SCs and Autologous SCs) by Therapeutic Application (Musculoskeletal Disorders, Wounds & Injuries, Cardiovascular Diseases, Gastrointestinal Diseases, Immune System Diseases, and Others), by Cell Source (Adipose Tissue-Derived Mesenchymal SCs, Bone Marrow-Derived Mesenchymal SCs, Embryonic SCs, and Other Sources), and by End User (Hospitals and ASCs): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2024”. According to the report, global stem cell therapy market was valued at approximately USD 1328.22 million in 2017 and is expected to generate revenue of around USD 4759.27 billion by the end of 2024, growing at a CAGR of around 20% between 2018 and 2024.
Stem cell therapy is a technique used to treat various types of diseases with the use of stem cells. Stem cells are the type of cells which can differentiate into the different type of organs & tissues. Increase in the adoption of stem cells therapy to treat diabetes, cancer, wounds, injuries, etc. and the growing investment by different companies & government for development of innovative & new technologies is expected to fuel the growth of global stem cell therapy market.
Browse the full "Stem Cell Therapy Market by Type (Allogenic SCs and Autologous SCs) by Therapeutic Application (Musculoskeletal Disorders, Wounds & Injuries, Cardiovascular Diseases, Gastrointestinal Diseases, Immune System Diseases, and Others), by Cell Source (Adipose Tissue-Derived Mesenchymal SCs, Bone Marrow-Derived Mesenchymal SCs, Embryonic SCs, and Other Sources), and by End User (Hospitals and ASCs): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2024" report at https://www.zionmarketresearch.com/report/stem-cell-therapy-market
Stem cells therapy market is segmented on the type, therapeutic application, cell source, and end user. On the basis of type, stem cell therapy market is segmented into autologous stem cells & allogenic stem cells. The allogenic SCs segment is projected to grow at the highest growth rate in the forecast period owing to the rise in the commercialization of allogenic SC therapy, and large therapeutic applications of allogenic SC.
Therapeutic application segment includes musculoskeletal disorders, immune system diseases, gastrointestinal diseases, cardiovascular diseases, wounds & injuries, and others. Cardiovascular disease segment is expected to dominate the market in the forecast period.
Based on cell source, the market is segmented into adipose tissue-derived mesenchymal SCs, embryonic SCs, bone-marrow-derived mesenchymal SCs, and others. Embryonic SCs dominate the market as it is easy to obtain as compared to the adult stem cells. Embryonic SCs also easily differentiate into the organ cells which also fuels the growth of the embryonic SCs segment.
On the basis of the end user, the stem cell therapy market is segmented ASCs and hospital. The hospital segment is expected to dominate the stem cell therapy market in the forecast period.
Europe, North America, Latin America, Asia Pacific, and the Middle East & Africa are the regional segments for the stem cell therapy market. North America is anticipated to dominate the market in the forecast period due to the increase in the prevalence of diseases which can be treated by stem cell therapy & increase in adoption of these therapies. Europe is the expected to be the second lucrative market after North America. The rapid increase in investment in the healthcare industry and an increase in awareness of stem cell therapy among the population for treatment is expected to stimulate the growth of the European stem cell therapy market. North America and Europe are followed by the Asia Pacific. Asia Pacific is expected to show the highest CAGR in the forecast period due to rising investments by government & other funding agencies for the scientific research & development of new innovative stem cells products & therapies. Also, the rapid increase in the investments by major players in economies such as China and India for the launching and development of their products in this region is fueling the stem cell therapy market. Latin America and the Middle East & Africa regions are expected to show lower growth rate in the forecast period.
The main players involved in the global market of stem cell therapy are Anterogen Co., Ltd., RTI Surgical, Inc., Pharmicell Co., Ltd., MEDIPOST Co., Ltd., JCR Pharmaceuticals Co., Ltd., Holostem Terapie Avanzate S.r.l., NuVasive, Inc., and AlloSource. The major companies are involved in strategic acquisition & mergers for global expansion & development of their R&D capabilities.
This report segments the global stem cell therapy market as follows:
Global Stem Cell Therapy Market: Type Segment Analysis
Global Stem Cell Therapy Market: Therapeutic Application Segment Analysis
Global Stem Cell Therapy Market: Cell Source Segment Analysis
Global Stem Cell Therapy Market: End-User Segment Analysis
Global Stem Cell Therapy Market: Regional Segment Analysis
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651